Medications for Anorexia Nervosa: Adjunctive Pharmacotherapy in Comprehensive Treatment

Anorexia nervosa (AN) is a serious psychiatric disorder characterized by restrictive eating, fear of weight gain, and body image disturbance. No medication directly treats the core psychopathology of AN (restriction, overvaluation of weight/shape). However, pharmacotherapy plays an important adjunctive role in comprehensive treatment.

Evidence-Based Pharmacologic Options

Selective Serotonin Reuptake Inhibitors (SSRIs)

  • Fluoxetine (Prozac) is the most studied; approved for bulimia nervosa, used off-label for AN.
  • Benefits: Reduces comorbid depression, anxiety, obsessive-compulsive symptoms; may modestly improve appetite and reduce rigidity.
  • Limitations: Less effective in acutely underweight state (malnutrition alters serotonin synthesis); weight gain effect is modest and inconsistent.
  • Dosing: Often higher doses (40-80 mg/day) than for depression alone.

Atypical Antipsychotics

  • Olanzapine (Zyprexa) has the strongest evidence base for AN.
  • Benefits: Reduces agitation, obsessive food/weight thoughts, cognitive rigidity; promotes weight gain (via H1 histamine antagonism) and improves sleep.
  • Risks: Metabolic side effects (weight gain beyond restoration, dyslipidemia, glucose dysregulation), QTc prolongation, sedation. Requires monitoring.
  • Other agents: Quetiapine, risperidone, aripiprazole—less evidence; used if olanzapine contraindicated.

Medications as Part of Multimodal Treatment

Pharmacotherapy is never standalone for AN. The treatment hierarchy:

  1. Nutritional rehabilitation: Weight restoration is the non-negotiable foundation; reverses starvation-induced neuroendocrine changes.
  2. Psychotherapy: CBT-E (enhanced cognitive behavioral therapy) for adults; FBT (family-based treatment) for adolescents—both first-line.
  3. Medical monitoring: Electrolytes, cardiac, bone density, endocrine.
  4. Pharmacotherapy: Adjunctive for comorbid symptoms, rigidity, anxiety—facilitates engagement in psychotherapy and nutritional recovery.

Emerging and Investigational Approaches

  • Psychedelic-assisted therapy: Psilocybin, MDMA trials for treatment-resistant AN (early phase).
  • Ghrelin agonists, oxytocin, neurosteroids: Preclinical/early clinical.
  • Repurposed agents: Mirtazapine (appetite stimulation, sleep), dronabinol (limited evidence).

Key Principles

  • Medication decisions are individualized—no universal protocol.
  • Start low, go slow; malnourished patients are medication-sensitive.
  • Regular reassessment: discontinue if no benefit after adequate trial.
  • Multidisciplinary team (psychiatrist, therapist, dietitian, physician) coordination is essential.

Recovery from anorexia nervosa is possible. While medications don't "cure" the disorder, they can reduce suffering, lower barriers to nutritional rehabilitation, and support the hard work of psychotherapy. Hope and healing exist—specialized eating disorder programs offer the best outcomes.

Anorexia - Related Articles